The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a landmark multi-center study launched in 2004 to define the progression of Alzheimer's Disease (AD).[1] ADNI has become one of the most influential research programs in Alzheimer's Disease, with data from over 1,000 participants followed for more than 15 years.[2] [1:1]
ADNI employs a longitudinal cohort design with three main diagnostic groups: [2:1]
ADNI collects multiple imaging modalities: [3:1]
ADNI established the hypothetical model of dynamic biomarkers showing that amyloid changes occur first, followed by neurodegeneration, then cognitive decline.[16] This model has become foundational for understanding AD progression. [4:1]
The accumulation of brain amyloid follows a predictable timeline, with amyloid plaques appearing 10-15 years before clinical symptoms.[17] [5:1]
Tau and neurodegeneration markers correlate strongly with cognitive decline and are predictive of progression from MCI to AD.[18] [6:1]
Recent ADNI analyses have validated plasma biomarkers including Aβ42/40 ratio, p-tau181, and p-tau217 for early detection.[19] [7:1]
ADNI has transformed clinical trial design by: [8:1]
ADNI involves over 50 sites across North America, including major research universities and medical centers. The study is funded by the National Institute on Aging (NIA) and other partners. [9:1]
ADNI data are publicly available through the ADNI LONI Image and Data Archive (IDA), enabling researchers worldwide to conduct secondary analyses.[24] [10:1]
ADNI continues to evolve with: [11:1]
The study of Alzheimer'S Disease Neuroimaging Initiative (Adni) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [12:1]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [13:1]
Additional evidence sources: [14:1] [15:1] [16:1] [17:1] [18:1] [19:1] [20:1] [21:1] [22:1] [23:1] [24:1] [25:1]
Weiner MW, et al. Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials. 2025. ↩︎ ↩︎
Mueller SG, et al. The Alzheimer's Disease Neuroimaging Initiative. 2005. ↩︎ ↩︎
Petersen RC, et al. Alzheimer's Disease Neuroimaging Initiative: clinical characterization. 2010. ↩︎ ↩︎
Winblad B, et al. Mild cognitive impairment beyond controversies. 2015. ↩︎ ↩︎
McKhann GM, et al. The diagnosis of dementia due to Alzheimer's Disease. 2011. ↩︎ ↩︎
Jack CR Jr, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. 2010. ↩︎ ↩︎
Jack CR Jr, et al. Tracking pathophysiological processes in Alzheimer's Disease. 2013. ↩︎ ↩︎
Aisen PS, et al. Clinical trial designs for disease-modifying therapies. 2011. ↩︎ ↩︎
Cummings JL, et al. Alzheimer's Disease drug development pipeline. 2023. ↩︎ ↩︎
Frisoni GB, et al. Hippocampal volume measurements in MCI. 2010. ↩︎ ↩︎
Mathis CA, et al. Development of PET radioligands for amyloid. 2005. ↩︎ ↩︎
Zetterberg H, Blennow K. Fluid biomarkers for early AD. 2023. ↩︎ ↩︎
Saykin AJ, et al. Genetic and epigenetic studies in ADNI. 2010. ↩︎ ↩︎
Jack CR Jr, et al. Amyloid-first and neurodegeneration-first profiles. 2013. ↩︎ ↩︎
Jansen WJ, et al. Prevalence of amyloid PET positivity. 2015. ↩︎ ↩︎
Hansson O, et al. Association between CSF biomarkers and progression. 2019. ↩︎ ↩︎
Schindler SE, et al. High-precision plasma amyloid biomarkers. 2019. ↩︎ ↩︎
Visser PJ, et al. Use of biomarkers for enrichment. 2019. ↩︎ ↩︎
Hendrix SB, et al. Sample size calculations for clinical trials. 2015. ↩︎ ↩︎
Cano SJ, et al. Cognitive outcome measures in clinical trials. 2019. ↩︎ ↩︎
Aizenstein HJ, et al. Surrogate endpoints in AD trials. 2014. ↩︎ ↩︎
ADNI Data Use Agreement and Access Procedures. ADNI LONI Archive. ↩︎ ↩︎
Weiner MW, et al. ADNI 3: continued innovation for clinical trial improvement. 2017. ↩︎ ↩︎